{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T02:17:24Z","timestamp":1768529844323,"version":"3.49.0"},"reference-count":65,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.lungcan.2023.01.010","type":"journal-article","created":{"date-parts":[[2023,1,21]],"date-time":"2023-01-21T10:59:05Z","timestamp":1674298745000},"page":"75-86","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Systemic treatment and radiotherapy for patients with non-small cell lung cancer (NSCLC) and HIV infection \u2013 A systematic review"],"prefix":"10.1016","volume":"178","author":[{"given":"Mariana","family":"Brand\u00e3o","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Val\u00e9rie","family":"Durieux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ma\u0161a","family":"Auprih","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Fozza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Dauby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Cuccia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandrine","family":"Aspeslagh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marthe","family":"Verhaert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niccol\u00f2","family":"Giaj-Levra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2023.01.010_b0005","unstructured":"WHO - HIV Key Facts 2021 [Internet]. [cited 2022 Oct 17]. Available from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hiv-aids."},{"issue":"8","key":"10.1016\/j.lungcan.2023.01.010_b0010","doi-asserted-by":"crossref","first-page":"e349","DOI":"10.1016\/S2352-3018(17)30066-8","article-title":"Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies","volume":"4","author":"Trickey","year":"2017","journal-title":"Lancet HIV"},{"issue":"3","key":"10.1016\/j.lungcan.2023.01.010_b0015","doi-asserted-by":"crossref","first-page":"e380","DOI":"10.1200\/JOP.2014.002709","article-title":"Cancer treatment in patients with HIV infection and non-AIDS-defining cancers: a survey of US oncologists","volume":"11","author":"Suneja","year":"2015","journal-title":"J. Oncol. Pract."},{"issue":"21","key":"10.1016\/j.lungcan.2023.01.010_b0020","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1200\/JCO.2014.59.5967","article-title":"Elevated cancer-specific mortality among HIV-infected patients in the United States","volume":"33","author":"Coghill","year":"2015","journal-title":"JCO"},{"issue":"7","key":"10.1016\/j.lungcan.2023.01.010_b0025","doi-asserted-by":"crossref","first-page":"e379","DOI":"10.1016\/S1470-2045(17)30440-0","article-title":"Radiotherapy in patients with HIV: current issues and review of the literature","volume":"18","author":"Alongi","year":"2017","journal-title":"Lancet Oncol."},{"issue":"9","key":"10.1016\/j.lungcan.2023.01.010_b0030","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1093\/jnci\/djr076","article-title":"Cancer burden in the HIV-infected population in the United States","volume":"103","author":"Shiels","year":"2011","journal-title":"JNCI: J. Natl. Cancer Inst."},{"issue":"10","key":"10.1016\/j.lungcan.2023.01.010_b0035","doi-asserted-by":"crossref","first-page":"e700","DOI":"10.1016\/S2352-3018(22)00219-3","article-title":"Trends and risk of lung cancer among people living with HIV in the USA: a population-based registry linkage study","volume":"9","author":"Haas","year":"2022","journal-title":"Lancet HIV"},{"issue":"9","key":"10.1016\/j.lungcan.2023.01.010_b0040","doi-asserted-by":"crossref","first-page":"e224","DOI":"10.1093\/cid\/ciaa1016","article-title":"Deaths attributable to cancer in the US human immunodeficiency virus population during 2001\u20132015","volume":"72","author":"Horner","year":"2021","journal-title":"Clin. Infect. Dis."},{"issue":"12","key":"10.1016\/j.lungcan.2023.01.010_b0045","doi-asserted-by":"crossref","first-page":"866","DOI":"10.7326\/M17-2499","article-title":"Projected cancer incidence rates and burden of incident cancer cases in HIV-infected adults in the united states through 2030","volume":"168","author":"Shiels","year":"2018","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.lungcan.2023.01.010_b0050","doi-asserted-by":"crossref","first-page":"iv192","DOI":"10.1093\/annonc\/mdy275","article-title":"Metastatic non-small cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Planchard","year":"2018","journal-title":"Ann. Oncol."},{"issue":"11","key":"10.1016\/j.lungcan.2023.01.010_b0055","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann. Intern. Med."},{"issue":"4","key":"10.1016\/j.lungcan.2023.01.010_b0060","first-page":"500","article-title":"Lung cancer in HIV positive patients: the GICAT experience","volume":"18","author":"Bearz","year":"2014","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"issue":"6","key":"10.1016\/j.lungcan.2023.01.010_b0065","doi-asserted-by":"crossref","first-page":"396","DOI":"10.3816\/CLC.2010.n.051","article-title":"Human immunodeficiency virus-associated primary lung cancer in the era of highly active antiretroviral therapy: a multi-institutional collaboration","volume":"11","author":"D\u2019Jaen","year":"2010","journal-title":"Clin. Lung Cancer"},{"issue":"1","key":"10.1016\/j.lungcan.2023.01.010_b0070","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1002\/cncr.26242","article-title":"Human immunodeficiency virus-associated lung cancer in the era of highly active antiretroviral therapy","volume":"118","author":"Pakkala","year":"2012","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.lungcan.2023.01.010_b0075","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1385\/MO:21:2:109","article-title":"Lung cancer in patients with HIV Infection and review of the literature","volume":"21","author":"Spano","year":"2004","journal-title":"Med. Oncol."},{"issue":"5","key":"10.1016\/j.lungcan.2023.01.010_b0080","doi-asserted-by":"crossref","first-page":"765","DOI":"10.3892\/mco.2017.1214","article-title":"Single-institutional experience of clinicopathological analysis and treatment for lung cancer patients with human immunodeficiency virus infection","volume":"6","author":"Takahashi","year":"2017","journal-title":"Mol. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.lungcan.2023.01.010_b0085","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.lungcan.2008.11.018","article-title":"Effect of highly active antiretroviral therapy on survival of HIV infected patients with non-small-cell lung cancer","volume":"65","author":"Lavol\u00e9","year":"2009","journal-title":"Lung Cancer"},{"issue":"2","key":"10.1016\/j.lungcan.2023.01.010_b0090","doi-asserted-by":"crossref","first-page":"1902066","DOI":"10.1183\/13993003.02066-2019","article-title":"First-line carboplatin plus pemetrexed with pemetrexed maintenance in HIV-positive patients with advanced non-squamous non-small cell lung cancer: the phase II IFCT-1001 CHIVA trial","volume":"56","author":"Lavole","year":"2020","journal-title":"Eur. Respir. J."},{"issue":"6","key":"10.1016\/j.lungcan.2023.01.010_b0095","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1097\/JTO.0b013e318217b6e0","article-title":"Human immunodeficiency virus infection and non-small cell lung cancer: survival and toxicity of antineoplastic chemotherapy in a cohort study","volume":"6","author":"Makinson","year":"2011","journal-title":"J. Thorac. Oncol."},{"issue":"10","key":"10.1016\/j.lungcan.2023.01.010_b0100","first-page":"586","article-title":"Concomitant chemoradiotherapy and antiretroviral therapy for HIV-infected patients with locoregionally advanced non-small cell lung cancer: benefit and tolerability of treatment in 2 cases","volume":"36","author":"Okuma","year":"2013","journal-title":"Onkologie"},{"issue":"5","key":"10.1016\/j.lungcan.2023.01.010_b0105","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1007\/s10147-011-0316-1","article-title":"Clinical characteristics of Japanese lung cancer patients with human immunodeficiency virus infection","volume":"17","author":"Okuma","year":"2012","journal-title":"Int. J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.lungcan.2023.01.010_b0110","first-page":"198","article-title":"Lung cancer in patients infected with human immunodeficiency virus. Clinical course and therapeutic implications","volume":"27","author":"Peyrade","year":"1998","journal-title":"Presse Med."},{"issue":"3","key":"10.1016\/j.lungcan.2023.01.010_b0115","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/sj.bjc.6601111","article-title":"Does HIV adversely influence the outcome in advanced non-small-cell lung cancer in the era of HAART?","volume":"89","author":"Powles","year":"2003","journal-title":"Br. J. Cancer"},{"issue":"8","key":"10.1016\/j.lungcan.2023.01.010_b0120","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1097\/CJI.0000000000000240","article-title":"Nivolumab treatment for cancers in the HIV-infected population","volume":"41","author":"Chang","year":"2018","journal-title":"J. Immunother."},{"key":"10.1016\/j.lungcan.2023.01.010_b0125","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.lungcan.2021.05.031","article-title":"Assessment of nivolumab in HIV-Infected patients with advanced non-small cell lung cancer after prior chemotherapy. The IFCT-1602 CHIVA2 phase 2 clinical trial","volume":"158","author":"Lavole","year":"2021","journal-title":"Lung Cancer"},{"issue":"7","key":"10.1016\/j.lungcan.2023.01.010_b0130","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.jtho.2018.03.031","article-title":"Safety and efficacy of PD-1 inhibitors among HIV-positive patients with non-small cell lung cancer","volume":"13","author":"Ostios-Garcia","year":"2018","journal-title":"J. Thoracic Oncol."},{"issue":"11","key":"10.1016\/j.lungcan.2023.01.010_b0135","doi-asserted-by":"crossref","first-page":"F13","DOI":"10.1097\/QAD.0000000000002298","article-title":"Immunotherapy for cancer in people living with HIV: safety with an efficacy signal from the series in real life experience","volume":"33","author":"Spano","year":"2019","journal-title":"AIDS"},{"issue":"9","key":"10.1016\/j.lungcan.2023.01.010_b0140","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1001\/jamaoncol.2019.2244","article-title":"Assessment of the safety of pembrolizumab in patients with HIV and advanced cancer-A Phase 1 study","volume":"5","author":"Uldrick","year":"2019","journal-title":"JAMA Oncol."},{"issue":"7","key":"10.1016\/j.lungcan.2023.01.010_b0145","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1001\/jamaoncol.2020.0465","article-title":"Assessment of the feasibility and safety of durvalumab for treatment of solid tumors in patients with HIV-1 infection: the Phase 2 DURVAST study","volume":"6","author":"Gonzalez-Cao","year":"2020","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.lungcan.2023.01.010_b0150","first-page":"111","article-title":"Lung cancer patients harboring epidermal growth factor receptor mutation among those infected by human immunodeficiency virus","volume":"8","author":"Okuma","year":"2015","journal-title":"Oncol. Targets Ther."},{"key":"10.1016\/j.lungcan.2023.01.010_b0155","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.lungcan.2015.11.021","article-title":"EGFR and KRAS mutation status in non-small-cell lung cancer occurring in HIV-infected patients","volume":"96","author":"Cr\u00e9quit","year":"2016","journal-title":"Lung Cancer"},{"issue":"6","key":"10.1016\/j.lungcan.2023.01.010_b0160","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1269\/jrr.10090","article-title":"Acute adverse effects of radiation therapy on HIV-positive patients in Japan: study of 31 cases at Tokyo Metropolitan Komagome Hospital","volume":"51","author":"Kaminuma","year":"2010","journal-title":"J. Radiat. Res."},{"issue":"2","key":"10.1016\/j.lungcan.2023.01.010_b0165","doi-asserted-by":"crossref","first-page":"e93","DOI":"10.1016\/S2352-3018(18)30295-9","article-title":"Contributions of traditional and HIV-related risk factors on non-AIDS-defining cancer, myocardial infarction, and end-stage liver and renal diseases in adults with HIV in the USA and Canada: a collaboration of cohort studies","volume":"6","author":"Althoff","year":"2019","journal-title":"Lancet HIV"},{"issue":"3","key":"10.1016\/j.lungcan.2023.01.010_b0170","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1097\/QAI.0b013e3181eef4f7","article-title":"Pulmonary infections and risk of lung cancer among persons with AIDS","volume":"55","author":"Shebl","year":"2010","journal-title":"J. Acquir. Immune Defic. Syndr."},{"issue":"2","key":"10.1016\/j.lungcan.2023.01.010_b0175","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1097\/QAD.0000000000001691","article-title":"HIV is associated with airway obstruction: a matched controlled study","volume":"32","author":"Makinson","year":"2018","journal-title":"AIDS"},{"issue":"2","key":"10.1016\/j.lungcan.2023.01.010_b0180","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.1016\/S2352-3018(16)30215-6","article-title":"Immunological and infectious risk factors for lung cancer in US veterans with HIV: a longitudinal cohort study","volume":"4","author":"Sigel","year":"2017","journal-title":"Lancet HIV"},{"issue":"8","key":"10.1016\/j.lungcan.2023.01.010_b0185","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1158\/1055-9965.EPI-14-1079","article-title":"Survival among HIV-infected and HIV-uninfected individuals with common non-AIDS-defining cancers","volume":"24","author":"Marcus","year":"2015","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"issue":"4","key":"10.1016\/j.lungcan.2023.01.010_b0190","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1097\/QAD.0000000000002810","article-title":"Impact of HIV infection on baseline characteristics and survival of women with breast cancer","volume":"35","author":"Brand\u00e3o","year":"2021","journal-title":"AIDS"},{"issue":"12","key":"10.1016\/j.lungcan.2023.01.010_b0195","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/j.annonc.2021.08.1994","article-title":"ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Early and locally advanced non-small-cell lung cancer: an update of the ESMO Clinical Practice Guidelines focusing on diagnosis, staging, systemic and local therapy","volume":"32","author":"Remon","year":"2021","journal-title":"Ann. Oncol."},{"issue":"14","key":"10.1016\/j.lungcan.2023.01.010_b0200","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1200\/JCO.19.03136","article-title":"Updated analysis from KEYNOTE-189: pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non-small-cell lung cancer","volume":"38","author":"Gadgeel","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.lungcan.2023.01.010_b0205","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1097\/JTO.0b013e3181d3ccf2","article-title":"Interactions between cytotoxic chemotherapy and antiretroviral treatment in human immunodeficiency virus-infected patients with lung cancer","volume":"5","author":"Makinson","year":"2010","journal-title":"J. Thorac. Oncol."},{"issue":"8","key":"10.1016\/j.lungcan.2023.01.010_b0210","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1111\/hiv.13268","article-title":"Major revision version 11.0 of the European AIDS Clinical Society Guidelines 2021","volume":"23","author":"Ryom","year":"2022","journal-title":"HIV Med."},{"key":"10.1016\/j.lungcan.2023.01.010_b0215","doi-asserted-by":"crossref","unstructured":"Reid E, Suneja G, Ambinder RF, Ard K, Baiocchi R, Barta SK, et al. Cancer in People Living With HIV, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology. J. Natl. Compr. Canc. Netw. 2018;16(8):986\u20131017.","DOI":"10.6004\/jnccn.2018.0066"},{"issue":"8","key":"10.1016\/j.lungcan.2023.01.010_b0220","doi-asserted-by":"crossref","first-page":"ofab389","DOI":"10.1093\/ofid\/ofab389","article-title":"Risks of opportunistic infections in people with human immunodeficiency virus with cancers treated with chemotherapy","volume":"8","author":"Makinson","year":"2021","journal-title":"Open Forum Infect. Dis."},{"issue":"23","key":"10.1016\/j.lungcan.2023.01.010_b0225","doi-asserted-by":"crossref","first-page":"12808","DOI":"10.3390\/ijms222312808","article-title":"Cytochrome P450 enzymes and drug metabolism in humans","volume":"22","author":"Zhao","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.lungcan.2023.01.010_b0230","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(11)70393-X","article-title":"Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial","volume":"13","author":"Rosell","year":"2012","journal-title":"Lancet Oncol."},{"issue":"10","key":"10.1016\/j.lungcan.2023.01.010_b0235","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJMoa0810699","article-title":"Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma","volume":"361","author":"Mok","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.lungcan.2023.01.010_b0240","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/S1470-2045(19)30634-5","article-title":"Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"20","author":"Nakagawa","year":"2019","journal-title":"Lancet Oncol."},{"issue":"33","key":"10.1016\/j.lungcan.2023.01.010_b0245","doi-asserted-by":"crossref","first-page":"3774","DOI":"10.1200\/JCO.2017.73.7338","article-title":"Modernizing clinical trial eligibility criteria: recommendations of the American society of clinical oncology-friends of cancer research HIV working group","volume":"35","author":"Uldrick","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.lungcan.2023.01.010_b0250","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"17","key":"10.1016\/j.lungcan.2023.01.010_b0255","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.lungcan.2023.01.010_b0260","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1016\/j.jtho.2016.05.021","article-title":"The international epidemiology of lung cancer: latest trends, disparities, and tumor characteristics","volume":"11","author":"Cheng","year":"2016","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2023.01.010_b0265","unstructured":"WHO facts - HIV\/AIDS in Africa [Internet]. WHO | Regional Office for Africa. [cited 2022 Oct 17]. Available from: https:\/\/www.afro.who.int\/health-topics\/hivaids."},{"issue":"4","key":"10.1016\/j.lungcan.2023.01.010_b0270","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1097\/QAD.0000000000001713","article-title":"Nonsmall cell lung cancer from HIV-infected patients expressed programmed cell death-ligand 1 with marked inflammatory infiltrates","volume":"32","author":"Domblides","year":"2018","journal-title":"AIDS"},{"issue":"7","key":"10.1016\/j.lungcan.2023.01.010_b0275","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1001\/jamaoncol.2017.0115","article-title":"Association of HIV status with local immune response to anal squamous cell carcinoma: implications for immunotherapy","volume":"3","author":"Yanik","year":"2017","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.lungcan.2023.01.010_b0280","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.oraloncology.2017.12.014","article-title":"HLA class I antigen processing machinery (APM) component expression and PD-1:PD-L1 pathway activation in HIV-infected head and neck cancers","volume":"77","author":"Pai","year":"2018","journal-title":"Oral Oncol."},{"issue":"7","key":"10.1016\/j.lungcan.2023.01.010_b0285","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19072000","article-title":"Immune checkpoints as the immune system regulators and potential biomarkers in HIV-1 infection","volume":"19","author":"Sperk","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.lungcan.2023.01.010_b0290","doi-asserted-by":"crossref","unstructured":"Gill AL, Green SA, Abdullah S, Le Saout C, Pittaluga S, Chen H, et al. Programed death-1\/programed death-ligand 1 expression in lymph nodes of HIV infected patients: results of a pilot safety study in rhesus macaques using anti-programed death-ligand 1 (Avelumab). AIDS. 2016 23;30(16):2487\u201393.","DOI":"10.1097\/QAD.0000000000001217"},{"issue":"2","key":"10.1016\/j.lungcan.2023.01.010_b0295","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1093\/annonc\/mdx696","article-title":"Drastic decrease of the HIV reservoir in a patient treated with nivolumab for lung cancer","volume":"29","author":"Guihot","year":"2018","journal-title":"Ann. Oncol."},{"issue":"6","key":"10.1016\/j.lungcan.2023.01.010_b0300","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.3390\/cells11061015","article-title":"Impact of Anti PD-1 immunotherapy on HIV reservoir and anti-viral immune responses in people living with HIV and cancer","volume":"11","author":"Baron","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.lungcan.2023.01.010_b0305","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.873701","article-title":"Evolving strategies to eliminate the CD4 T cells HIV viral reservoir via CAR T cell immunotherapy","volume":"13","author":"York","year":"2022","journal-title":"Front. Immunol."},{"issue":"9","key":"10.1016\/j.lungcan.2023.01.010_b0310","doi-asserted-by":"crossref","first-page":"e690","DOI":"10.1016\/S2352-3026(20)30142-3","article-title":"CAR T-cell therapy for cancer and HIV through novel approaches to HIV-associated haematological malignancies","volume":"7","author":"Rust","year":"2020","journal-title":"Lancet Haematol."},{"issue":"10274","key":"10.1016\/j.lungcan.2023.01.010_b0315","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/S0140-6736(21)00228-2","article-title":"Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial","volume":"397","author":"Sezer","year":"2021","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.lungcan.2023.01.010_b0320","doi-asserted-by":"crossref","first-page":"S214","DOI":"10.1016\/j.jtho.2019.08.424","article-title":"OA04.02 CheckMate 817: first-line Nivolumab + Ipilimumab in patients with ECOG PS 2 and other special populations with advanced NSCLC","volume":"14","author":"Barlesi","year":"2019","journal-title":"J. Thoracic Oncol."},{"issue":"7","key":"10.1016\/j.lungcan.2023.01.010_b0325","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.jtho.2018.03.031","article-title":"Safety and efficacy of PD-1 inhibitors among HIV-positive patients with non-small cell lung cancer","volume":"13","author":"Ostios-Garcia","year":"2018","journal-title":"J. Thorac. Oncol."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500223000399?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500223000399?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T13:05:20Z","timestamp":1759237520000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500223000399"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":65,"alternative-id":["S0169500223000399"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2023.01.010","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Systemic treatment and radiotherapy for patients with non-small cell lung cancer (NSCLC) and HIV infection \u2013 A systematic review","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2023.01.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}